INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $921,169 | -24.6% | 219,326 | 0.0% | 0.21% | -26.2% |
| Q2 2023 | $1,221,646 | -2.8% | 219,326 | 0.0% | 0.29% | -11.9% |
| Q1 2023 | $1,256,738 | +445.7% | 219,326 | 0.0% | 0.33% | +391.0% |
| Q4 2022 | $230,292 | +23.8% | 219,326 | +216.4% | 0.07% | +26.4% |
| Q3 2022 | $186,000 | -43.8% | 69,326 | 0.0% | 0.05% | -44.8% |
| Q2 2022 | $331,000 | +386.8% | 69,326 | +314.5% | 0.10% | +540.0% |
| Q1 2022 | $68,000 | -40.4% | 16,726 | 0.0% | 0.02% | -34.8% |
| Q4 2021 | $114,000 | -41.2% | 16,726 | 0.0% | 0.02% | -45.2% |
| Q3 2021 | $194,000 | -31.9% | 16,726 | 0.0% | 0.04% | -30.0% |
| Q2 2021 | $285,000 | -13.9% | 16,726 | 0.0% | 0.06% | -18.9% |
| Q1 2021 | $331,000 | -4.1% | 16,726 | 0.0% | 0.07% | -11.9% |
| Q4 2020 | $345,000 | -21.6% | 16,726 | 0.0% | 0.08% | -17.6% |
| Q3 2020 | $440,000 | – | 16,726 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |